RU2005141759A - Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений - Google Patents
Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений Download PDFInfo
- Publication number
- RU2005141759A RU2005141759A RU2005141759/15A RU2005141759A RU2005141759A RU 2005141759 A RU2005141759 A RU 2005141759A RU 2005141759/15 A RU2005141759/15 A RU 2005141759/15A RU 2005141759 A RU2005141759 A RU 2005141759A RU 2005141759 A RU2005141759 A RU 2005141759A
- Authority
- RU
- Russia
- Prior art keywords
- pharmaceutically acceptable
- angiotensin
- antagonist
- cholesterol lowering
- lowering agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrotherapy Devices (AREA)
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
Claims (16)
1. Применение антагониста ангиотензина II, или его фармацевтически приемлемого производного, или фармацевтически приемлемой соли для производства лекарственного средства для профилактики или уменьшения сердечно-сосудистых явлений у пациентов с высоким риском, не имеющих признаков дисфункции левого желудочка или сердечной недостаточности, где сердечно-сосудистые явления представляют собой инсульт, сердечно-сосудистую смерть и инфаркт миокарда.
2. Применение по п.1, где пациенты имеют риск сердечно-сосудистых явлений из-за манифестировавшей ишемической болезни сердца, преходящих ишемических приступов или инсульта в анамнезе, или заболевания периферических сосудов в анамнезе.
3. Применение по п.1, где пациенты больны диабетом.
4. Применение по любому из пп.1-3, где антагонист ангиотензина II представляет собой саралазинацетат, кандесартан цилексетил, валсартан, кандесартан, лосартан калия, эпросартан, ирбесартан, тазосартан или телмисартан, или их фармацевтически приемлемые производные.
5. Применение по любому из пп.1-3, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании с другим антигипертензивным средством, понижающим содержание холестерина средством, мочегонным средством или аспирином.
6. Применение по п.5, где антигипертензивным средством является блокатор кальциевого канала или бета-блокатор.
7. Применение по любому из пп.1-3, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании со средством, понижающим содержание холестерина.
8. Применение по п.7, где средством, понижающим содержание холестерина, является статин.
9. Применение по п.8, где статином является ловастатин, правастатин, симвастатин или флювастатин.
10. Применение антагониста ангиотензина II, или его фармацевтически приемлемого производного, или фармацевтически приемлемой соли для производства лекарственного средства для профилактики или уменьшения диабета у пациентов с высоким риском, не имеющих признаков дисфункции левого желудочка или сердечной недостаточности.
11. Применение по п.10, где антагонист ангиотензина II представляет собой саралазинацетат, кандесартан цилексетил, валсартан, кандесартан, лосартан калия, эпросартан, ирбесартан, тазосартан или телмисартан, или их фармацевтически приемлемые производные.
12. Применение по п.10 или 11, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании с другим антигипертензивным средством, понижающим содержание холестерина средством, мочегонным средством или аспирином.
13. Применение по п.12, где антигипертензивным средством является блокатор кальциевого канала или бета-блокатор.
14. Применение по п.10 или 11, где антагонист ангиотензина II или его фармацевтически приемлемая соль используются в сочетании со средством, понижающим содержание холестерина.
15. Применение по п.14, где средством, понижающим содержание холестерина, является статин.
16. Применение по п.15, где статином является ловастатин, правастатин, симвастатин или флювастатин.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15143699P | 1999-08-30 | 1999-08-30 | |
| US60/151,436 | 1999-08-30 | ||
| US60/151.436 | 1999-08-30 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002107985/15A Division RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2005141759A true RU2005141759A (ru) | 2007-07-10 |
Family
ID=22538761
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002107985/15A RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
| RU2005141759/15A RU2005141759A (ru) | 1999-08-30 | 2005-12-30 | Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2002107985/15A RU2276997C2 (ru) | 1999-08-30 | 2000-08-30 | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений |
Country Status (31)
| Country | Link |
|---|---|
| US (4) | US20040087645A1 (ru) |
| EP (1) | EP1216038B1 (ru) |
| JP (1) | JP4870888B2 (ru) |
| KR (2) | KR20120055730A (ru) |
| CN (1) | CN1268331C (ru) |
| AT (1) | ATE303800T1 (ru) |
| AU (3) | AU7649100A (ru) |
| BG (2) | BG110003A (ru) |
| BR (1) | BR0013704A (ru) |
| CA (1) | CA2382549C (ru) |
| CZ (1) | CZ300687B6 (ru) |
| DE (1) | DE60022525T2 (ru) |
| DK (1) | DK1216038T3 (ru) |
| EE (1) | EE05670B1 (ru) |
| ES (1) | ES2246894T3 (ru) |
| HK (1) | HK1048267B (ru) |
| HR (1) | HRP20020170A2 (ru) |
| HU (1) | HUP0203326A3 (ru) |
| IL (2) | IL148127A0 (ru) |
| ME (1) | ME00429B (ru) |
| MX (1) | MXPA02001694A (ru) |
| NO (1) | NO331616B1 (ru) |
| NZ (2) | NZ517468A (ru) |
| PL (1) | PL353199A1 (ru) |
| RS (1) | RS50377B (ru) |
| RU (2) | RU2276997C2 (ru) |
| SK (1) | SK2692002A3 (ru) |
| TR (1) | TR200200515T2 (ru) |
| UA (2) | UA77151C2 (ru) |
| WO (1) | WO2001015674A2 (ru) |
| ZA (1) | ZA200201470B (ru) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1498124E (pt) * | 1997-10-17 | 2007-10-16 | Boehringer Ingelheim Int | Utilização de inibidores do sistema renina-angiotensina |
| CN101011390A (zh) * | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
| SE9903028D0 (sv) * | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AU7649100A (en) * | 1999-08-30 | 2001-03-26 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| NZ546884A (en) * | 2000-08-22 | 2008-05-30 | Boehringer Ingelheim Pharma | Co-administration of an angiotensin II (ANG II) antagonist and an ACE inhibitor for treating congestive heart failure |
| AR033390A1 (es) * | 2000-08-22 | 2003-12-17 | Novartis Ag | Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes |
| GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
| US20060089389A1 (en) * | 2000-08-22 | 2006-04-27 | Malcolm Allison | Combination |
| AU2001284413A1 (en) * | 2000-08-30 | 2002-03-13 | Sankyo Company Limited | Medicinal compositions for preventing or treating heart failure |
| US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
| GB0119460D0 (en) * | 2001-08-09 | 2001-10-03 | Ark Therapeutics Ltd | The use of inhibitors of the renin-angiotensin system |
| US6576256B2 (en) | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| CA2463682A1 (en) * | 2001-10-17 | 2003-04-24 | Aventis Pharma Deutschland Gmbh | Method of reducing type 2 diabetes in high risk patients |
| CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
| DE10229180A1 (de) * | 2002-06-28 | 2004-01-29 | Aventis Pharma Deutschland Gmbh | Verwendung von Vasopeptidase-Inhibitoren bei der Behandlung von metabolischen Erkrankungen, Nephropathie und mit AGE assoziierten Erkrankungen |
| EP1382334A1 (en) * | 2002-07-11 | 2004-01-21 | Université de Picardie Jules Verne | Use of angiotensin II AT1-receptor blockers (ARB), alone or combined with thiazide or angiotensin II for the treatment of stroke |
| US6936639B2 (en) * | 2002-08-21 | 2005-08-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Nitroxyl progenitors in the treatment of heart failure |
| JP2006504800A (ja) * | 2002-10-16 | 2006-02-09 | レコーダチ アイルランド リミテッド | リシノプリル／レルカニジピンの組み合わせ治療 |
| DE10301371A1 (de) * | 2003-01-16 | 2004-08-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten |
| JP2006515877A (ja) * | 2003-01-16 | 2006-06-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心臓血管、心肺、肺又は腎疾患の予防又は治療のための医薬併用剤 |
| ME00479B (me) | 2003-01-31 | 2011-10-10 | Daiichi Sankyo Co Ltd | Lijek za profilaksu i tretman arterioskleroze i hipertenzije |
| US7169805B2 (en) * | 2003-05-28 | 2007-01-30 | Nicox S.A. | Captopril derivatives |
| CA2532450C (en) * | 2003-07-16 | 2012-09-11 | Boehringer Ingelheim International Gmbh | Chlorthalidone combinations |
| AU2004261212B2 (en) | 2003-07-28 | 2011-01-27 | Dr. Reddy's Laboratories Ltd. | Treatment and prevention of cardiovascular events |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| TW200523257A (en) * | 2003-09-26 | 2005-07-16 | Novartis Ag | Use of organic compounds |
| TW200605867A (en) * | 2004-03-17 | 2006-02-16 | Novartis Ag | Use of organic compounds |
| RU2384346C2 (ru) * | 2004-06-23 | 2010-03-20 | Зольвай Фармасьютиклз Гмбх | Фармацевтические композиции, содержащие nep-ингибиторы, ингибиторы эндогенной эндотелинпродуцирующей системы и антагонисты at1-рецептора |
| JP4675586B2 (ja) * | 2004-06-23 | 2011-04-27 | 壽製薬株式会社 | 高血圧症及び血清高尿酸血症の重複発症の治療のための薬剤 |
| CN101098681A (zh) * | 2004-11-05 | 2008-01-02 | 国王医药研究与发展有限公司 | 稳定化的单个涂布的雷米普利颗粒、组合物和方法 |
| JP2008528456A (ja) * | 2005-01-26 | 2008-07-31 | レツク・フアーマシユーテイカルズ・デー・デー | 親油性結晶性物質としてカンデサルタンシレキセチルを含む新規な医薬組成物 |
| EP1898951B1 (en) * | 2005-06-27 | 2013-02-27 | Daiichi Sankyo Company, Limited | Pharmaceutical preparation containing an angiotensin ii receptor antagonist and a calcium channel blocker |
| US8158146B2 (en) | 2005-09-28 | 2012-04-17 | Teva Pharmaceutical Industries Ltd. | Stable combinations of amlodipine besylate and benazepril hydrochloride |
| WO2007053406A1 (en) * | 2005-10-28 | 2007-05-10 | Novartis Ag | Combinations of antihypertensive and cholesterol lowering agents |
| US20070116756A1 (en) * | 2005-11-23 | 2007-05-24 | Dr. Reddy's Laboratories Limited | Stable pharmaceutical compositions |
| US20070185065A1 (en) * | 2006-02-03 | 2007-08-09 | Vikramjit Chhokar | Combination therapy for coronary artery disease |
| BRPI0716411A2 (pt) * | 2006-08-28 | 2013-09-24 | Sanofi Aventis Deutschland | mÉtodos para o abaixamento dos nÍveis de glicose |
| TWI399223B (zh) * | 2006-09-15 | 2013-06-21 | Daiichi Sankyo Co Ltd | 奧美沙坦酯及氨氯地平之固體劑型 |
| US8394845B2 (en) | 2006-10-30 | 2013-03-12 | Hanall Biopharma Co., Ltd. | Method of using combination preparation comprising angiotensin-II-receptor blocker and HMG-CoA reductase inhibitor |
| US20100143470A1 (en) * | 2006-10-30 | 2010-06-10 | Hanall Pharmaceutical Company, Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
| CA2664893C (en) * | 2006-10-30 | 2015-01-27 | Hanall Pharmaceutical Company, Ltd. | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| NZ596064A (en) * | 2009-04-30 | 2014-03-28 | Reddy’S Lab Ltd Dr | Fixed dose drug combination formulations |
| US20110160200A1 (en) * | 2009-11-23 | 2011-06-30 | Cardioxyl Pharmaceuticals, Inc. | Nitroxyl Progenitors for the Treatment of Pulmonary Hypertension |
| MX356796B (es) * | 2009-12-07 | 2018-06-14 | Cardioxyl Pharmaceuticals Inc | Derivados de hidroxilamina bis-acilados. |
| JP5826762B2 (ja) * | 2009-12-07 | 2015-12-02 | ザ ジョンズ ホプキンス ユニバーシティ | Ｎ−アシルオキシスルホンアミドおよびｎ−ヒドロキシ−ｎ−アシルスルホンアミド誘導体 |
| WO2011104588A2 (en) | 2010-02-24 | 2011-09-01 | Sanofi-Aventis Deutschland Gmbh | Solid pharmaceutical formulations of ramipril and amlodipine besylate, and their preparation |
| WO2012087090A1 (es) * | 2010-12-21 | 2012-06-28 | Laboratorios Silanes S.A. De C.V. | Composición estable de agentes reductores de colesterol, antihipertensivos y antiagregantes plaquetarios |
| BR102012020648A2 (pt) * | 2012-08-17 | 2014-12-09 | Hypermarcas S A | Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido |
| KR101579656B1 (ko) * | 2013-12-12 | 2015-12-22 | 가천대학교 산학협력단 | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 |
| CN110833620A (zh) * | 2018-08-15 | 2020-02-25 | 王镕 | 血管紧张素转化酶抑制剂在防治自身免疫性疾病及相应的并发症中的用途 |
Family Cites Families (122)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5612114B2 (ru) * | 1974-06-07 | 1981-03-18 | ||
| US4231938A (en) * | 1979-06-15 | 1980-11-04 | Merck & Co., Inc. | Hypocholesteremic fermentation products and process of preparation |
| US4444784A (en) * | 1980-08-05 | 1984-04-24 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| DK149080C (da) * | 1980-06-06 | 1986-07-28 | Sankyo Co | Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre |
| US4450171A (en) * | 1980-08-05 | 1984-05-22 | Merck & Co., Inc. | Antihypercholesterolemic compounds |
| ZA817261B (en) * | 1980-10-23 | 1982-09-29 | Schering Corp | Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them |
| DE3226768A1 (de) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | Derivate der cis, endo-2-azabicyclo-(3.3.0)-octan-3-carbonsaeure, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung |
| US4448784A (en) * | 1982-04-12 | 1984-05-15 | Hoechst-Roussel Pharmaceuticals, Inc. | 1-(Aminoalkylphenyl and aminoalkylbenzyl)-indoles and indolines and analgesic method of use thereof |
| US4739073A (en) * | 1983-11-04 | 1988-04-19 | Sandoz Pharmaceuticals Corp. | Intermediates in the synthesis of indole analogs of mevalonolactone and derivatives thereof |
| US4722810A (en) * | 1984-08-16 | 1988-02-02 | E. R. Squibb & Sons, Inc. | Enkephalinase inhibitors |
| US5684016A (en) * | 1984-04-12 | 1997-11-04 | Hoechst Aktiengesellschaft | Method of treating cardiac insufficiency |
| DE3413710A1 (de) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur behandlung der herzinsuffizienz |
| CH672792A5 (ru) | 1985-02-19 | 1989-12-29 | Sandoz Ag | |
| US5231080A (en) * | 1985-10-15 | 1993-07-27 | Hoechst Aktiengesellschaft | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease |
| EP0241201A3 (en) | 1986-04-07 | 1990-05-23 | Merck & Co. Inc. | Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure |
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US4749688A (en) * | 1986-06-20 | 1988-06-07 | Schering Corporation | Use of neutral metalloendopeptidase inhibitors in the treatment of hypertension |
| DE3633496A1 (de) * | 1986-10-02 | 1988-04-14 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit calciumantagonisten sowie deren verwendung in arzneimitteln |
| FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
| DE3704661A1 (de) * | 1987-02-14 | 1988-08-25 | Hoechst Ag | Annelierte azepinon- und azocinon-derivate, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung, sowie zwischenprodukte bei ihrer herstellung |
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| JPH0657707B2 (ja) | 1987-05-25 | 1994-08-03 | 吉富製薬株式会社 | ピペリジン化合物 |
| DE3739690A1 (de) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen |
| EP0331014A3 (de) | 1988-03-02 | 1991-10-23 | THERA - Patent Verwaltungs-GmbH | Verwendung von ACE-Inhibitoren für die Diabetesprophylaxe |
| US5217958A (en) * | 1988-03-03 | 1993-06-08 | E. R. Squibb & Sons, Inc. | 1,2-hydroxy phosphonates and derivatives thereof |
| US4804770A (en) * | 1988-04-29 | 1989-02-14 | E. R. Squibb & Sons, Inc. | Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors |
| DE3818245A1 (de) * | 1988-05-28 | 1989-12-07 | Hoechst Ag | Kombination von angiotensin-converting-enzyme-hemmern mit kaliumkanal-modulatoren sowie deren verwendung in arzneimitteln |
| MY105067A (en) | 1988-10-13 | 1994-07-30 | Novartis Ag | Process for the preparation of 7-substituted-hept-6-enoic and -heptanoic acids and derivatives and intermediates thereof. |
| WO1990005531A1 (en) * | 1988-11-21 | 1990-05-31 | Abbott Laboratories | Method for treating vascular diseases |
| CA2016467A1 (en) * | 1989-06-05 | 1990-12-05 | Martin Eisman | Method for treating peripheral atherosclerotic disease employing an hmg coa reductase inhibitor and/or a squalene synthetase inhibitor |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| DE3926606A1 (de) * | 1989-08-11 | 1991-02-14 | Hoechst Ag | Verfahren zur behandlung der cardialen sowie der vasculaeren hypertrophie und hyperplasie |
| US5061694A (en) * | 1989-10-23 | 1991-10-29 | E. R. Squibb & Sons, Inc. | Method for stabilizing or causing regression of atherosclerosis in coronary arteries employing an ace inhibitor |
| US5212165A (en) * | 1989-10-23 | 1993-05-18 | E. R. Squibb & Sons, Inc. | Method for rehabilitating the vasorelaxant action of the coronary arteries impaired through atherosclerosis or hypercholesterolemia employing an ace inhibitor |
| CA2026686A1 (en) | 1989-10-30 | 1991-05-01 | Werner Tschollar | Method for preventing onset of type ii diabetes employing an ace inhibitor |
| US5223516A (en) * | 1990-03-22 | 1993-06-29 | E. R. Squibb & Sons, Inc. | 3,3,3-trifluoro-2-mercaptomethyl-N-tetrazolyl substituted propanamides and method of using same |
| US5196444A (en) * | 1990-04-27 | 1993-03-23 | Takeda Chemical Industries, Ltd. | 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof |
| CA2040865C (en) | 1990-05-15 | 2002-07-23 | James L. Bergey | Method for preventing, stabilizing or causing regression of atherosclerosis employing a combination of a cholesterol lowering drug and an ace inhibitor |
| US5298497A (en) * | 1990-05-15 | 1994-03-29 | E. R. Squibb & Sons, Inc. | Method for preventing onset of hypertension employing a cholesterol lowering drug |
| US5166143A (en) * | 1990-05-31 | 1992-11-24 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing an ace inhibitor |
| US5140012A (en) | 1990-05-31 | 1992-08-18 | E. R. Squibb & Sons, Inc. | Method for preventing onset of restenosis after angioplasty employing pravastatin |
| US5622985A (en) * | 1990-06-11 | 1997-04-22 | Bristol-Myers Squibb Company | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor |
| CA2042526A1 (en) | 1990-06-11 | 1991-12-12 | Adeoye Y. Olukotun | Method for preventing a second heart attack employing an hmg coa reductase inhibitor |
| CA2048699A1 (en) | 1990-09-04 | 1992-03-05 | Abraham Sudilovsky | Method for preventing or treating cerebro-vascular disease employing ceronapril |
| US5470975A (en) * | 1990-10-16 | 1995-11-28 | E.R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5430145A (en) * | 1990-10-18 | 1995-07-04 | Merrell Dow Pharmaceuticals Inc. | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| US5190970A (en) * | 1990-10-19 | 1993-03-02 | E. R. Squibb & Sons, Inc. | Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| CA2052014A1 (en) | 1990-10-19 | 1992-04-20 | Henry Y. Pan | Method for preventing diabetic complications employing a cholesterol lowering drug alone or in combination with an ace inhibitor |
| US5130333A (en) * | 1990-10-19 | 1992-07-14 | E. R. Squibb & Sons, Inc. | Method for treating type II diabetes employing a cholesterol lowering drug |
| GB9027199D0 (en) | 1990-12-14 | 1991-02-06 | Smithkline Beecham Plc | Medicaments |
| US5157025A (en) | 1991-04-01 | 1992-10-20 | E. R. Squibb & Sons, Inc. | Method for lowering serum cholesterol employing a phosphorus containing ace inhibitor alone or in combination with a cholesterol lowering drug |
| JPH05112533A (ja) | 1991-05-08 | 1993-05-07 | Upjohn Co:The | イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤 |
| US5506361A (en) * | 1991-05-08 | 1996-04-09 | Theupjohn Company | Imidazobenzoquinones and composition for preventing or treating hypertension or congestive heart failure containing the same |
| GB9110635D0 (en) * | 1991-05-16 | 1991-07-03 | Glaxo Group Ltd | Chemical compounds |
| US5225401A (en) * | 1991-08-12 | 1993-07-06 | E. R. Squibb & Sons, Inc. | Treatment of congestive heart failure |
| US5256667A (en) * | 1991-09-25 | 1993-10-26 | Merck & Co., Inc. | Quinazolinones and pyridopyrimidinones |
| US5202322A (en) * | 1991-09-25 | 1993-04-13 | Merck & Co., Inc. | Quinazolinone and pyridopyrimidine a-II antagonists |
| CA2078759C (en) | 1991-09-27 | 2003-09-16 | Alan M. Warshawsky | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace |
| AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| JPH06107661A (ja) | 1991-10-24 | 1994-04-19 | Upjohn Co:The | イミダゾール誘導体およびこれを有効成分とする医薬組成物 |
| US5350752A (en) | 1991-12-16 | 1994-09-27 | E. R. Squibb & Sons, Inc. | Dihydropyrimidine derivatives |
| DK9200258U4 (da) | 1992-03-11 | 1993-07-23 | Merck & Co Inc | Farmaceutisk præparat indeholdende enalapril til brug mod hypertension |
| US5219856A (en) * | 1992-04-06 | 1993-06-15 | E. I. Du Pont De Nemours And Company | Angiotensin-II receptor blocking, heterocycle substituted imidazoles |
| US5972990A (en) * | 1992-04-10 | 1999-10-26 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5977160A (en) * | 1992-04-10 | 1999-11-02 | Brigham And Women's Hospital, Inc. | Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims |
| US5552397A (en) * | 1992-05-18 | 1996-09-03 | E. R. Squibb & Sons, Inc. | Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase |
| HU223663B1 (hu) * | 1992-05-15 | 2004-11-29 | Merrel Dow Pharmaceuticals Inc. | Enkefalináz és ACE gátló hatású 9-[(2-acetil-tio-3-fenil)-propanoil-amino]-piridazo[1,2-a][1,2]diazepin-származékok, eljárás előállításukra, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények |
| WO1994002142A1 (en) * | 1992-07-17 | 1994-02-03 | Merck & Co., Inc. | Substituted biphenylmethylimidazopyridines |
| US5266583A (en) * | 1992-09-01 | 1993-11-30 | Merck & Co., Inc. | Angitotensin II antagonist |
| WO1994007492A1 (en) | 1992-10-06 | 1994-04-14 | The Upjohn Company | Use of 4-hydrazono-1,4-dihydro-pyridine and/or 4-hydrazino-pyridine derivatives for treatment of hypertension and congestive heart failure |
| US5504080A (en) * | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
| GB9223860D0 (en) * | 1992-11-13 | 1993-01-06 | Glaxo Group Ltd | Chemical compounds |
| DE4308504A1 (de) | 1993-03-18 | 1994-09-22 | Knoll Ag | Neue Verwendung einer Kombination aus Verapamil und Trandolapril |
| DE4309553A1 (de) * | 1993-03-24 | 1994-09-29 | Bayer Ag | Verfahren zur Herstellung von 3R,5S-(+)-Natrium-erythro-(E)-7-(4-(4-flurophenyl)-2,6-diisopropyl-5-methoxymethyl-pyrid-3-yl)-3,5-dihydroxy-hept-6-enoat |
| HUT71494A (en) * | 1993-06-11 | 1995-11-28 | Eisai Co Ltd | Pharmaceutical compositions containing of condensed heterocyclic amino acid derivatives |
| US5508272A (en) * | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| US5362772A (en) * | 1993-07-09 | 1994-11-08 | E. I. Du Pont De Nemours And Company | Crosslinked microgel for cathodic electrocoating compositions |
| US5362727A (en) * | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| WO1995013063A1 (en) | 1993-11-09 | 1995-05-18 | Merck & Co., Inc. | HMG-CoA REDUCTASE INHIBITORS IN THE NORMALIZATION OF VASCULAR ENDOTHELIAL DYSFUNCTION |
| US5525723A (en) * | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
| US6369103B1 (en) | 1994-01-18 | 2002-04-09 | Bristol-Myers Squibb Company | Method for preventing or reducing risk of onset of cardiovascular events employing an HMG CoA reductase inhibitor |
| ES2079315B1 (es) * | 1994-02-24 | 1996-10-16 | Uriach & Cia Sa J | Nuevas imidazopiridinas. |
| IL112639A0 (en) | 1994-03-11 | 1995-05-26 | Bristol Myers Squibb Co | A pharmaceutical composition containing pravastin |
| WO1995026188A1 (en) | 1994-03-29 | 1995-10-05 | Merck & Co., Inc. | Treatment of atherosclerosis with angiotensin ii receptor blocking imidazoles |
| ES2105939B1 (es) * | 1994-08-02 | 1998-07-01 | Uriach & Cia Sa J | Nuevos pirazoles con actividad antagonista de la angiotensina ii. |
| US5612359A (en) * | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| TW483763B (en) | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| BR9604882A (pt) | 1995-02-10 | 1998-05-19 | Searle & Co | Terapia de combinação de inibidor de enzima de conversão de antgiotensina e quantidade de efeito colateral reduzido de antagonista de aldosterona para tratamento de doença cardiovascular |
| EP0738510A3 (fr) | 1995-04-20 | 2005-12-21 | L'oreal | Utilisation d'un inhibiteur d'HMG-coenzyme A-reductase pour lutter contre le vieillissement de la peau et pour traiter l'acné. Composition comprenant au moins un inhibiteur HMG-coenzyme A reductase et au moins un actif possédant des propriétes desquamantes |
| US5656603A (en) * | 1995-05-31 | 1997-08-12 | Loyola University Of Chicago | Aminopeptidase P inhibitors and uses thereof |
| ES2175098T3 (es) | 1995-06-07 | 2002-11-16 | Searle & Co | Terapia de combinacion de espironolactona y antagonista de angiotensina hi para el tratamiento del fallo cardiaco congestivo. |
| TW442301B (en) | 1995-06-07 | 2001-06-23 | Sanofi Synthelabo | Pharmaceutical compositions containing irbesartan |
| GB2308064A (en) | 1995-10-31 | 1997-06-18 | Merck & Co Inc | Treatment of congestive heart failure with a growth hormone secretagogue |
| WO1997027745A1 (en) | 1996-01-31 | 1997-08-07 | Technology Licensing Co. L.L.C. | Method of diagnosis and treatment and related compositions and apparatus |
| EP0795327A1 (en) * | 1996-03-13 | 1997-09-17 | Pfizer Inc. | Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin |
| CA2257946A1 (en) | 1996-06-24 | 1997-12-31 | Merck & Co., Inc. | A composition of enalapril and losartan |
| JPH1081633A (ja) * | 1996-07-16 | 1998-03-31 | Sankyo Co Ltd | 医薬組成物 |
| PT966282E (pt) | 1997-01-10 | 2003-10-31 | Merck & Co Inc | Uso de antagonistas da angiotensina ii para tratar a insuficiencia cardiaca sintomatica |
| US6180660B1 (en) * | 1997-08-26 | 2001-01-30 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| CA2300165A1 (en) | 1997-08-26 | 1999-03-04 | Merck & Co., Inc. | Cholesterol-lowering therapy |
| GT199800126A (es) | 1997-08-29 | 2000-01-29 | Terapia de combinacion. | |
| PT1498124E (pt) | 1997-10-17 | 2007-10-16 | Boehringer Ingelheim Int | Utilização de inibidores do sistema renina-angiotensina |
| ZA991706B (en) | 1998-03-04 | 2000-10-03 | Takeda Chemical Industries Ltd | Sustained-release preparation for Aii Antagonist, production and use thereof. |
| WO2000002543A2 (en) | 1998-07-10 | 2000-01-20 | Novartis Ag | Antihypersensitive combination of valsartan and calcium channel blocker |
| DE69915084T2 (de) | 1998-09-30 | 2004-07-22 | Warner-Lambert Co. Llc | Methode zur vermeidung oder verzögerung von katheterbedingter gefässrückbildung |
| US6403856B1 (en) * | 1998-10-19 | 2002-06-11 | Uop Llc | Process for separating alkylaromatic hydrocarbons |
| DE19913528A1 (de) | 1998-12-21 | 2000-06-29 | Sanol Arznei Schwarz Gmbh | Neue Verwendung von Moexipril |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| AU4988100A (en) | 1999-05-07 | 2000-11-21 | Brigham And Women's Hospital | Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization |
| WO2000071751A1 (en) | 1999-05-21 | 2000-11-30 | Myriad Genetics, Inc. | Diabetes gene |
| EP1076091A1 (en) | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| SE9903028D0 (sv) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| AU7649100A (en) * | 1999-08-30 | 2001-03-26 | Aventis Pharma Deutschland Gmbh | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| EP1212101A1 (en) | 1999-08-31 | 2002-06-12 | The Brigham And Women's Hospital, Inc. | Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| WO2001076632A1 (en) | 2000-04-10 | 2001-10-18 | Wald Nicholas J | Formulation for the prevention of cardiovascular disease |
| BR0109966A (pt) | 2000-04-12 | 2003-08-05 | Novartis Ag | Combinação de compostos orgânicos |
| WO2001078747A1 (de) | 2000-04-18 | 2001-10-25 | Bayer Aktiengesellschaft | Verwendung von cse-hemmern zur behandlung von herzinsuffizienz |
| GB0020691D0 (en) * | 2000-08-22 | 2000-10-11 | Boehringer Ingelheim Pharma | Pharmaceutical combination |
| US20030158090A1 (en) * | 2001-07-23 | 2003-08-21 | Ulrik Pedersen-Bjergaard | Renin-angiotensin system in diabetes mellitus |
| US20050065203A1 (en) * | 2001-10-17 | 2005-03-24 | Salim Yusuf | Method of reducing type 2 diabetes in high risk patients |
| CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
-
2000
- 2000-08-30 AU AU76491/00A patent/AU7649100A/en not_active Abandoned
- 2000-08-30 CN CNB008113947A patent/CN1268331C/zh not_active Expired - Fee Related
- 2000-08-30 TR TR2002/00515T patent/TR200200515T2/xx unknown
- 2000-08-30 BR BR0013704-9A patent/BR0013704A/pt not_active Application Discontinuation
- 2000-08-30 RU RU2002107985/15A patent/RU2276997C2/ru not_active IP Right Cessation
- 2000-08-30 EE EEP200200086A patent/EE05670B1/xx not_active IP Right Cessation
- 2000-08-30 WO PCT/EP2000/008461 patent/WO2001015674A2/en active Application Filing
- 2000-08-30 SK SK269-2002A patent/SK2692002A3/sk unknown
- 2000-08-30 AT AT00965906T patent/ATE303800T1/de active
- 2000-08-30 EP EP00965906A patent/EP1216038B1/en not_active Revoked
- 2000-08-30 PL PL00353199A patent/PL353199A1/xx not_active Application Discontinuation
- 2000-08-30 NZ NZ517468A patent/NZ517468A/en not_active IP Right Cessation
- 2000-08-30 CZ CZ20020770A patent/CZ300687B6/cs not_active IP Right Cessation
- 2000-08-30 KR KR1020127009682A patent/KR20120055730A/ko not_active Application Discontinuation
- 2000-08-30 CA CA002382549A patent/CA2382549C/en not_active Expired - Fee Related
- 2000-08-30 HU HU0203326A patent/HUP0203326A3/hu not_active Application Discontinuation
- 2000-08-30 ME MEP-2008-643A patent/ME00429B/me unknown
- 2000-08-30 JP JP2001519888A patent/JP4870888B2/ja not_active Expired - Fee Related
- 2000-08-30 ES ES00965906T patent/ES2246894T3/es not_active Expired - Lifetime
- 2000-08-30 MX MXPA02001694A patent/MXPA02001694A/es active IP Right Grant
- 2000-08-30 DK DK00965906T patent/DK1216038T3/da active
- 2000-08-30 KR KR1020027002626A patent/KR20020040795A/ko not_active Application Discontinuation
- 2000-08-30 UA UA2002032518A patent/UA77151C2/uk unknown
- 2000-08-30 RS YUP-85/02A patent/RS50377B/sr unknown
- 2000-08-30 IL IL14812700A patent/IL148127A0/xx unknown
- 2000-08-30 DE DE60022525T patent/DE60022525T2/de not_active Expired - Lifetime
-
2002
- 2002-01-28 BG BG110003A patent/BG110003A/bg unknown
- 2002-01-28 BG BG106360A patent/BG65474B1/bg unknown
- 2002-02-12 IL IL148127A patent/IL148127A/en unknown
- 2002-02-21 ZA ZA200201470A patent/ZA200201470B/en unknown
- 2002-02-26 HR HR20020170A patent/HRP20020170A2/xx not_active Application Discontinuation
- 2002-02-27 NO NO20020978A patent/NO331616B1/no not_active IP Right Cessation
-
2003
- 2003-01-23 HK HK03100570.5A patent/HK1048267B/zh not_active IP Right Cessation
- 2003-10-28 US US10/694,001 patent/US20040087645A1/en not_active Abandoned
-
2004
- 2004-01-20 NZ NZ530702A patent/NZ530702A/en not_active IP Right Cessation
- 2004-12-02 US US11/001,028 patent/US20050101658A1/en not_active Abandoned
-
2005
- 2005-09-13 AU AU2005209687A patent/AU2005209687A1/en not_active Abandoned
- 2005-12-30 RU RU2005141759/15A patent/RU2005141759A/ru not_active Application Discontinuation
-
2006
- 2006-01-11 UA UAA200600263A patent/UA88265C2/ru unknown
- 2006-07-21 US US11/490,061 patent/US7368469B2/en not_active Expired - Lifetime
-
2008
- 2008-05-22 US US12/125,313 patent/US20080287403A1/en not_active Abandoned
-
2009
- 2009-02-25 AU AU2009200746A patent/AU2009200746B8/en not_active Ceased
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2005141759A (ru) | Применение антагонистов ингиотензина ii для профилактики сердечно-сосудистых явлений | |
| RU2002107985A (ru) | Применение ингибиторов ренин-ангиотензиновой системы для профилактики сердечно-сосудистых явлений | |
| JP2003527325A5 (ru) | ||
| RU2002129558A (ru) | КОМБИНАЦИЯ ПО МЕНЬШЕЙ МЕРЕ ДВУХ СОЕДИНЕНИЙ, ВЫБРАННЫХ ИЗ ГРУПП АНТАГОНИСТОВ АТ,-РЕЦЕПТОРА ИЛИ ИНГИБИТОРОВ АСЕ(АНГИОТЕНЗИНПРЕВРАЩАЮЩИЙ ФЕРМЕНТ) ИЛИ ИНГИБИТОРОВ HMG-COA-РЕДУКТАЗЫ (β-ГИДРОКСИ-β-МЕТИЛГЛУТАРИЛ-КОФЕРМЕНТ-А-РЕДУКТАЗА) | |
| IL160643A (en) | Orally administrable pharmaceutical dosage form containing a cholesterol lowering agent, a renin-angiotensin inhibitor and aspirin and a packaged kit | |
| RU2005128124A (ru) | Фармацевтические препараты и их применение для профилактики удара, диабета и/или застойной сердечной недостаточности | |
| CA2405793A1 (en) | Combination of organic compounds | |
| HRP20110969T4 (hr) | Pimobendan za upotrebu za smanjenje veličine srca kod sisavaca koji pate od srčane insuficijencije | |
| RU2006132668A (ru) | Синергетические комбинации, которые содержат ингибитор ренина, предназначенные для лечения сердечно-сосудистых заболеваний | |
| EP1314425A1 (en) | Medicinal compositions for preventing or treating heart failure | |
| RU2006117790A (ru) | Применение производного пиразола для получения лекарственного средства, пригодного для профилактики и лечения дислипидемий и заболеваний, связанных с дислипидемиями и/или с ожирением | |
| Lee | Retarding the progression of diabetic nephropathy in type 2 diabetes mellitus: focus on hypertension and proteinuria | |
| Ross et al. | Candesartan cilexetil in cardiovascular disease | |
| Meredith | Candesartan cilexetil–a review of effects on cardiovascular complications in hypertension and chronic heart failure | |
| JP2007522203A5 (ru) | ||
| Oparil et al. | Angiotensin receptor blocker and dihydropyridine calcium channel blocker combinations: an emerging strategy in hypertension therapy | |
| JP2002535367A5 (ru) | ||
| CN1750830A (zh) | 双嘧达莫与乙酰水杨酸及血管紧张素ⅱ拮抗剂的组合在预防中风中的应用 | |
| CA2360691A1 (en) | Use of angiotensin ii receptor antagonists for treating acute myocardial infarction | |
| Silverstein et al. | ARBs and target organ protection: exploring benefits beyond their antihypertensive effects | |
| KR20070111468A (ko) | 마니디핀과 스타틴의 치료용 복합물 | |
| JP2005511631A (ja) | 脳血管障害発作の急性期における高血圧症の治療 | |
| Silverstein et al. | Angiotensin-receptor blockers: benefits beyond lowering blood pressure | |
| Kino et al. | Effect of an angiotensin II receptor antagonist, TCV-116, on rat carotid artery neointimal formation after balloon injury | |
| Julius | Bringing VALUE to LIFE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20100913 |